Sitemap | Contact Us

Daiichi-Sankyo

Home > Terms of Use and Privacy Policy

Terms of Use and Privacy Policy

Terms of Use and Privacy Policy

The content of this site is protected under applicable copyright and trademark laws. You may print a single copy of the content for your own personal non-commercial use. The further copying, redistribution, or publication of any part of this site is prohibited. Daiichi Sankyo, Inc. makes no representations as to the availability, accuracy, or completeness of the content of this site.

Daiichi Sankyo, Inc. shall not be liable for any damages or injuries resulting from your access to, or inability to access, this site or from your reliance on any information at this site. Daiichi Sankyo, Inc. may collect data from you that you provide to us voluntarily such as your name, postal address, email address, telephone number, and other personal information. The information we collect is used to improve the content of our website, and may be used to contact you, via email or by regular mail, to provide you with information that we believe may be of interest to you. We do not sell or transfer the information you send to us to others outside our company, except that your data may be transferred to an outside fulfillment company for processing and mailing purposes, or for market research purposes. Data which is not personal, including questions, comments, ideas and suggestions, shall be deemed to be non-confidential, and Daiichi Sankyo, Inc. shall be free to disclose and use the same, without any obligations whatsoever towards you, for any purpose and through any means.

This site is controlled and operated from the United States. The information on this site is designed to comply with the laws of the United States and is intended for use by U.S. residents only. Daiichi Sankyo, Inc. makes no representation that materials in this site are appropriate or applicable for use in other countries. The information provided on this site is for general educational and informational purposes only. Such information is not meant to be a substitute for advice provided by a physician or other qualified healthcare professional.

Our site may provide links or references to other websites not affiliated with Daiichi Sankyo, Inc. Daiichi Sankyo, Inc. believes its links provide helpful information; however, Daiichi Sankyo, Inc. is not responsible for the content of such other sites and shall not be liable for any damages or injuries arising from your access to such sites. Links to other sites are provided only as a convenience to users of our site. This privacy policy is current as of the date on this page. Any changes made to this privacy policy will be posted on the website within thirty (30) days of the change.

Updated 10/07

GET UPDATES

Be notified of new patient educational materials, site
updates, and more.

SIGN UP NOW

Indication

BENICAR and BENICAR HCT are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. BENICAR HCT is not indicated for initial therapy.

Important Safety Information

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, BENICAR or BENICAR HCT should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality in the prescribing information.

Hypotension in Volume- or Salt-Depleted Patients
In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with BENICAR. Treatment should start under close medical supervision. If hypotension does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.

Impaired Renal Function
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.

The prescribing information for BENICAR HCT also includes the following warnings regarding its hydrochlorothiazide component:

  • BENICAR HCT is not recommended in patients with severe renal impairment, and is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs

Fetal/Neonatal Morbidity and Mortality
Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.

Hepatic Impairment
Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Hypersensitivity Reaction
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.

Systemic Lupus Erythematosus
Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.

Lithium Interaction
Lithium generally should not be given with thiazides.

Adverse Events

  • The withdrawal rates due to adverse events (AEs) were similar with BENICAR and BENICAR HCT to placebo: BENICAR (2.4% vs. 2.7%); BENICAR HCT (2.0% vs. 2.0%)
  • The incidence of AEs with BENICAR and BENICAR HCT was similar to placebo
    • The only AE that occurred in >1% of patients treated with BENICAR and more frequently than placebo was dizziness (3% vs. 1%)
    • AEs reported in >2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs. 0%), hyperuricemia (4% vs. 2%), dizziness (9% vs. 2%), and upper respiratory tract infection (7% vs. 0%)

Dosing and Administration

  • No initial dosage adjustments are recommended with BENICAR in elderly or in moderate to marked renal impairment*/hepatic dysfunction
    • In patients with possible depletion of intravascular volume (eg, patients on diuretics, particularly with impaired renal function), BENICAR should be initiated under close medical supervision and consideration given to use of a lower starting dose
  • For BENICAR HCT, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range

*Creatinine clearance <40 mL/min

Please see full prescribing information for BENICAR and BENICAR HCT.

The information on this page is intended to be used by U.S. healthcare professionals only. Patients and consumers are directed to BENICAR and BENICAR HCT Product Information.

The photos depict models, not actual patients or healthcare professionals.

Benicar and Benicar HCT are promoted by Daiichi Sankyo, Inc.
© 2008 Daiichi Sankyo, Inc.

DCSIMG